

SUPPLEMENTAL TABLE 1. Baseline characteristics of HIV-infected FRAM participants by Leg Muscle Tertile*

	Tertile 1 (lowest) (n = 310)	Tertile 2 (n = 314)	Tertile 3 (highest) (n = 298)	P-value
Age (y)	44.0 (38.0–50.0)	42.0 (36.0–49.0)	41.0 (36.0–46.0)	<.0001
Female	30%	29%	30%	0.84
Race: African-American	34%	37%	47%	0.0007
Caucasian	52%	53%	39%	
Other	14%	10%	14%	
Diabetes	6%	8%	12%	0.0023
Smoking Status: Current	47%	47%	34%	0.0012
Past	22%	21%	24%	
Never	31%	32%	42%	
Antihypertensive use	20%	20%	24%	0.22
ACE-I use	10%	8%	9%	0.57
Hyperlipidemia Treatment	14%	15%	18%	0.076
Systolic BP (mmHg)	113.0 (105.0–123.0)	115.0 (106.0–124.0)	118.0 (109.0–125.0)	0.0001
Diastolic BP (mmHg)	77.0 (70.0–83.0)	77.5 (70.0–83.0)	80.0 (73.0–87.0)	0.0001
Waist Circumference (cm)	84.0 (77.1–91.3)	87.8 (81.5–95.5)	94.3 (86.6–101.5)	<.0001
Total Cholesterol (mg/dL)	190.0 (161.0–230.0)	189.0 (154.0–232.0)	193.0 (162.0–218.0)	0.77
HDL (mg/dL)	43.0 (34.0–54.0)	40.0 (33.0–53.0)	40.0 (34.0–51.0)	0.052
CRP (mg/L)	2.2 (0.9–4.7)	1.6 (0.7–3.8)	1.7 (0.8–4.0)	0.036
Fibrinogen (mg/dL)	385 (314–474)	354 (284–421)	344 (293–409)	<.0001
eGFRcys (mL/min/1.73m ²)	80 (66–97)	86 (72–100)	89 (73–103)	<.0001
Albuminuria	24%	17%	21%	0.19
HIV-Related Factors				
Detectable HIVRNA	51%	46%	52%	0.91
Current CD4 count (cells/μL)	339 (169–566)	366 (225–509)	407 (247–566)	<.0001
Detectable HCVRNA	24%	23%	17%	0.021
History of AIDS **	70%	75%	68%	0.53
HAART use (ever)	90%	89%	86%	0.075

* Statistics estimated using IPCW weights. Continuous data are represented as median (IQR). Note: Leg SM is adjusted for height and then tertiled, with cutpoints of: T1 = <9.1 kg for women, <10.5 kg for men. T2 = 9.1–11.1 kg for women, 10.5–12.2 kg for men; T3 = >11.1 kg for women, >12.2 kg for men. ** AIDS defined by CD4<200 or history of opportunistic infection or malignancy

SUPPLEMENTAL TABLE 2. Association of MRI measures of muscle and adiposity with 5-year Mortality in HIV-infected FRAM participants, stratified by CD4 Count*

	Final model (all participants) OR (95% CI) P-value	Sensitivity Analysis restricted to CD4>200 OR (95% CI) P-value	Sensitivity Analysis restricted to CD4<200 OR (95% CI) P-value
Arm SM: T2 vs. T1	0.59 (0.35, 0.99) p=0.044	0.38 (0.18, 0.81) p=0.013	0.90 (0.36, 2.22) p=0.81
Arm SM: T3 vs. T1	0.51 (0.25, 1.04) p=0.062	0.46 (0.20, 1.05) p=0.065	0.28 (0.060, 1.32) p=0.10
VAT: T2 vs. T1	1.77 (1.03, 3.03) p=0.039	2.25 (1.05, 4.86) p=0.038	1.58 (0.65, 3.87) p=0.31
VAT: T3 vs. T1	2.12 (1.13, 3.98) p=0.019	2.54 (0.94, 6.88) p=0.065	2.05 (0.72, 5.80) p=0.18
Leg SM: T2 vs. T1	0.92 (0.54, 1.57) p=0.75	1.83 (0.92, 3.65) p=0.086	0.34 (0.14, 0.83) p=0.018
Leg SM: T3 vs. T1	0.42 (0.21, 0.84) p=0.015	0.78 (0.30, 2.02) p=0.60	0.16 (0.042, 0.58) p=0.0061

Estimates from multivariable adjusted models controlling for age, sex, race, traditional CVD risk factors, HIV-related factors, CRP, fibrinogen, eGFRcys, albuminuria, arm SM, leg SM, and VAT.

SUPPLEMENTAL TABLE 3. Baseline characteristics of HIV-infected FRAM participants by VAT Tertile*

	Tertile 1 (lowest) (n = 298)	Tertile 2 (n = 324)	Tertile 3 (highest) (n = 300)	P-value
Age (y)	41.0 (36.0–47.0)	42.0 (37.0–48.0)	44.0 (38.0–51.0)	<.0001
Female	30%	28%	31%	0.78
Race: African-American	57%	37%	24%	<.0001
Caucasian	32%	49%	63%	
Other	11%	15%	13%	
Diabetes	5%	7%	14%	<.0001
Smoking Status: Current	53%	40%	36%	<.0001
Past	18%	23%	26%	
Never	30%	38%	38%	
Antihypertensive use	15%	21%	29%	<.0001
ACE-I use	5%	10%	12%	0.0022
Hyperlipidemia Treatment	6%	15%	26%	<.0001
Systolic BP (mmHg)	112.0 (104.0–120.0)	115.0 (106.0–125.0)	119.0 (110.0–128.0)	<.0001
Diastolic BP (mmHg)	76.0 (69.0–80.0)	79.0 (71.0–84.0)	80.0 (72.0–88.0)	<.0001
Waist Circumference (cm)	79.6 (75.2–85.1)	88.1 (83.5–93.5)	97.4 (92.5–103.5)	<.0001
Total Cholesterol (mg/dL)	177.0 (147.0–210.0)	191.0 (160.0–226.0)	204.0 (169.0–245.0)	<.0001
HDL (mg/dL)	45.0 (36.0–57.0)	40.0 (33.0–52.0)	38.0 (32.0–48.0)	<.0001
CRP (mg/L)	1.4 (0.6–3.3)	1.7 (0.8–3.7)	2.5 (1.0–4.7)	<.0001
Fibrinogen (mg/dL)	363 (296–443)	352 (293–448)	370 (297–421)	0.34
eGFR _{cys} (mL/min/1.73m ²)	86 (72–103)	86 (72–103)	84 (69–98)	0.78
Albuminuria	21%	20%	22%	0.76
HIV-Related Factors				
Detectable HIVRNA	60%	48%	41%	<.0001
Current CD4 count (cells/μL)	286 (162–479)	385 (238–559)	438 (273–628)	<.0001
Detectable HCVRNA	26%	23%	14%	<.0001
History of AIDS **	74%	69%	68%	0.061
HAART use (ever)	87%	88%	89%	0.32

* Statistics estimated using IPCW weights. Continuous data are represented as median (IQR). Note: VAT is adjusted for height and then tertiled, with cutpoints of: T1 = <0.8 kg for women, <0.9 kg for men; T2 = 0.8–1.9 kg for women, 0.9–2.3 kg for men; T3 = >1.9 kg for women, >2.3 kg for men.

** AIDS defined by CD4<200 or history of opportunistic infection or malignancy